According to the latest data from the Hong Kong Stock Exchange, on October 14th, shareholders of BIOSTAR PHARM-B (02563) deposited shares with Huatai Hong Kong, with a custody market value of HK$125 million, representing 7.91% of the company's shares.
BIOSTAR PHARM-B released its interim results for the six months ended June 30, 2025, reporting operating revenue of RMB 14.787 million, a decrease of 55.36% year-on-year. The company recorded a net loss of RMB 54.041 million, which narrowed by 23.41% compared to the same period last year. Basic loss per share was RMB 0.15.